SYNPO2L

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, SYNPO2L mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SYNPO2L data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SYNPO2L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SYNPO2L expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC are the cancer types where SYNPO2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCDFSQuartileIII,IV0.8330.486.0374view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

SYNPO2L–HNSC (DFS)

Kaplan–Meier survival curve for SYNPO2L mass-spec protein-high vs -low samples in HNSC.

Open the HNSC breakdown →

Exploration